EVALUATION of GINGIVAL CREVICULAR FLUID and SERUM ASPROSIN LEVELS in OBESE and NORMAL-WEIGHT INDIVIDUALS with PERIODONTITIS

Obesity and periodontitis are chronic inflammatory diseases that share common pathological mechanisms. Asprosin, a novel adipokine discovered in 2016, has not been extensively studied in relation to periodontal tissues. In our study, we investigate the levels of asprosin in both serum and gingival crevicular fluid of patients with obesity and those of normal weight who have periodontitis. Additionally, our research aims to clarify the pathophysiological mechanisms linking periodontitis and obesity by examining local and systemic levels of TNF-α, IL-6, and asprosin, alongside clinical periodontal parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Periodontitis Arachnodactyly Body Weight Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Limb Deformities, Congenital Mouth Diseases Musculoskeletal Abnormalities Musculoskeletal Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Periodontal Diseases Signs and Symptoms Stomatognathic Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Gazi University Faculty of Dentistry

Ankara, 06490, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Willingness to participate in the study.
Weight classification:

Obese individuals: Body mass index (BMI) of 30 kg/m² or higher.
Normal-weight individuals: BMI between 18.5 and 24.9 kg/m².
Periodontal health status:

Bleeding on probing: less than 10%.
Periodontal pocket depth: less than 3 mm.
No sites showing attachment loss or alveolar bone loss on radiographs.
For individuals with periodontitis:

At least two non-adjacent teeth must show signs of interdental attachment loss.
Periodontal pocket depth greater than 3 mm.

Exclusion criteria

Individuals who have received periodontal therapy, any oral decontamination treatment, or antibiotics or steroids in the six months prior to the start of the study.
Individuals who are pregnant or breastfeeding.
Individuals diagnosed with rheumatoid arthritis or lupus erythematosus.
Individuals with a medical history of radiation or cancer therapy.
Patients with diabetes, defined by:

Hemoglobin A1c (HbA1c) level greater than 6.5%.
Fasting blood glucose (FBG) greater than 126 mg/dL.
An abnormal oral glucose tolerance test (OGTT).
Smokers.

Treatment and study plan

Participants are not assigned an intervention as part of the study.

Other

Participants are not assigned an intervention as part of the study.

Primary outcomes

Biyomarker levels

Time frame: 08.10.2023-08.10.2024

All groups' GCF and serum levels of asprosin, TNF-α, and IL-6 levels

Sponsors and collaborators

Lead sponsor

Gazi University

Other

Collaborators

Gazi University Scientific Research Unit

Registry information

Official study title

Evaluation of Serum and Gingival Crevicular Fluid Asprosin Levels in Obese and Normal-Weight Patients with Periodontitis

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Mar 17, 2025
Registry last updated: Mar 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed